Transscleral diode laser cyclophotocoagulation after baerveldt glaucoma implant surgery

Joseph F. Panarelli, Michael R. Banitt, Paul A. Sidoti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PURPOSE: To evaluate the safety and efficacy of transscleral cyclophotocoagulation (TSCPC) in patients requiring intraocular pressure (IOP) reduction despite prior Baerveldt glaucoma implant (BGI) surgery. PARTICIPANTS AND METHODS: Twenty eyes of 20 patients who had previously undergone BGI placement and subsequently underwent TSCPC with the red (810 nm) diode laser between April 2005 and January 2010 were retrospectively reviewed. RESULTS: All patients underwent BGI placement an average of 34.7±24.2 months before TSCPC. The mean follow-up period after TSCPC was 25.6±17.4 months (range, 2.3 to 56.5 mo). IOPs were reduced from a mean of 21.8±4.6 to 10.8±3.2 mm Hg at the most recent follow-up, which represents a 50.2% reduction in mean IOP. Successful postoperative IOP control was achieved in 16 (80%) of 20 patients. The number of glaucoma medications decreased from 4.2±0.6 to 2.2±1.2. The life-table success rate was 78.6% at 12, 24, and 36 months. Postoperative complications included persistent corneal edema in 1 patient and both persistent corneal edema and cystoid macular edema in another patient. Both patients sustained a >2 line reduction in Snellen visual acuity. CONCLUSIONS: TSCPC is safe and effective in the management of patients requiring IOP reduction after BGI surgery. Although our sample size was limited, the safety profile of TSCPC after BGI seems promising.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalJournal of Glaucoma
Volume23
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Glaucoma Drainage Implants
Semiconductor Lasers
Glaucoma
Intraocular Pressure
Corneal Edema
Safety
Life Tables
Macular Edema
Sample Size
Visual Acuity

Keywords

  • Baerveldt glaucoma implant
  • complications
  • outcomes
  • refractory glaucoma
  • transscleral diode laser cyclophotocoagulation

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Transscleral diode laser cyclophotocoagulation after baerveldt glaucoma implant surgery. / Panarelli, Joseph F.; Banitt, Michael R.; Sidoti, Paul A.

In: Journal of Glaucoma, Vol. 23, No. 6, 01.01.2014, p. 405-409.

Research output: Contribution to journalArticle

Panarelli, Joseph F. ; Banitt, Michael R. ; Sidoti, Paul A. / Transscleral diode laser cyclophotocoagulation after baerveldt glaucoma implant surgery. In: Journal of Glaucoma. 2014 ; Vol. 23, No. 6. pp. 405-409.
@article{e74570fa55b74e2bae72566748c7c0df,
title = "Transscleral diode laser cyclophotocoagulation after baerveldt glaucoma implant surgery",
abstract = "PURPOSE: To evaluate the safety and efficacy of transscleral cyclophotocoagulation (TSCPC) in patients requiring intraocular pressure (IOP) reduction despite prior Baerveldt glaucoma implant (BGI) surgery. PARTICIPANTS AND METHODS: Twenty eyes of 20 patients who had previously undergone BGI placement and subsequently underwent TSCPC with the red (810 nm) diode laser between April 2005 and January 2010 were retrospectively reviewed. RESULTS: All patients underwent BGI placement an average of 34.7±24.2 months before TSCPC. The mean follow-up period after TSCPC was 25.6±17.4 months (range, 2.3 to 56.5 mo). IOPs were reduced from a mean of 21.8±4.6 to 10.8±3.2 mm Hg at the most recent follow-up, which represents a 50.2{\%} reduction in mean IOP. Successful postoperative IOP control was achieved in 16 (80{\%}) of 20 patients. The number of glaucoma medications decreased from 4.2±0.6 to 2.2±1.2. The life-table success rate was 78.6{\%} at 12, 24, and 36 months. Postoperative complications included persistent corneal edema in 1 patient and both persistent corneal edema and cystoid macular edema in another patient. Both patients sustained a >2 line reduction in Snellen visual acuity. CONCLUSIONS: TSCPC is safe and effective in the management of patients requiring IOP reduction after BGI surgery. Although our sample size was limited, the safety profile of TSCPC after BGI seems promising.",
keywords = "Baerveldt glaucoma implant, complications, outcomes, refractory glaucoma, transscleral diode laser cyclophotocoagulation",
author = "Panarelli, {Joseph F.} and Banitt, {Michael R.} and Sidoti, {Paul A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/IJG.0b013e318279c957",
language = "English",
volume = "23",
pages = "405--409",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Transscleral diode laser cyclophotocoagulation after baerveldt glaucoma implant surgery

AU - Panarelli, Joseph F.

AU - Banitt, Michael R.

AU - Sidoti, Paul A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - PURPOSE: To evaluate the safety and efficacy of transscleral cyclophotocoagulation (TSCPC) in patients requiring intraocular pressure (IOP) reduction despite prior Baerveldt glaucoma implant (BGI) surgery. PARTICIPANTS AND METHODS: Twenty eyes of 20 patients who had previously undergone BGI placement and subsequently underwent TSCPC with the red (810 nm) diode laser between April 2005 and January 2010 were retrospectively reviewed. RESULTS: All patients underwent BGI placement an average of 34.7±24.2 months before TSCPC. The mean follow-up period after TSCPC was 25.6±17.4 months (range, 2.3 to 56.5 mo). IOPs were reduced from a mean of 21.8±4.6 to 10.8±3.2 mm Hg at the most recent follow-up, which represents a 50.2% reduction in mean IOP. Successful postoperative IOP control was achieved in 16 (80%) of 20 patients. The number of glaucoma medications decreased from 4.2±0.6 to 2.2±1.2. The life-table success rate was 78.6% at 12, 24, and 36 months. Postoperative complications included persistent corneal edema in 1 patient and both persistent corneal edema and cystoid macular edema in another patient. Both patients sustained a >2 line reduction in Snellen visual acuity. CONCLUSIONS: TSCPC is safe and effective in the management of patients requiring IOP reduction after BGI surgery. Although our sample size was limited, the safety profile of TSCPC after BGI seems promising.

AB - PURPOSE: To evaluate the safety and efficacy of transscleral cyclophotocoagulation (TSCPC) in patients requiring intraocular pressure (IOP) reduction despite prior Baerveldt glaucoma implant (BGI) surgery. PARTICIPANTS AND METHODS: Twenty eyes of 20 patients who had previously undergone BGI placement and subsequently underwent TSCPC with the red (810 nm) diode laser between April 2005 and January 2010 were retrospectively reviewed. RESULTS: All patients underwent BGI placement an average of 34.7±24.2 months before TSCPC. The mean follow-up period after TSCPC was 25.6±17.4 months (range, 2.3 to 56.5 mo). IOPs were reduced from a mean of 21.8±4.6 to 10.8±3.2 mm Hg at the most recent follow-up, which represents a 50.2% reduction in mean IOP. Successful postoperative IOP control was achieved in 16 (80%) of 20 patients. The number of glaucoma medications decreased from 4.2±0.6 to 2.2±1.2. The life-table success rate was 78.6% at 12, 24, and 36 months. Postoperative complications included persistent corneal edema in 1 patient and both persistent corneal edema and cystoid macular edema in another patient. Both patients sustained a >2 line reduction in Snellen visual acuity. CONCLUSIONS: TSCPC is safe and effective in the management of patients requiring IOP reduction after BGI surgery. Although our sample size was limited, the safety profile of TSCPC after BGI seems promising.

KW - Baerveldt glaucoma implant

KW - complications

KW - outcomes

KW - refractory glaucoma

KW - transscleral diode laser cyclophotocoagulation

UR - http://www.scopus.com/inward/record.url?scp=84905575138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905575138&partnerID=8YFLogxK

U2 - 10.1097/IJG.0b013e318279c957

DO - 10.1097/IJG.0b013e318279c957

M3 - Article

VL - 23

SP - 405

EP - 409

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

IS - 6

ER -